An observational study in Ischemic Heart Disease, sponsored by Hyeon-Cheol Gwon. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-02-09.
Sponsored by Hyeon-Cheol Gwon · Observational
Comparison of safety and long-term effects of BioMimeTM stent and Ultimaster® stent with Xience® stent
A prospective, open, multicenter, and observational study will register and compare Xience® groups treated in institutions such as the BioMime ™, Ultimaster® group prospectively registered from June 2016.
The Xience® group has already been registered in the previous study (SMARTDESK-BX), so BioMimeTM and Ultimaster® only need to be registered. Follow-up will be conducted until December 2019, and e-CRF will be completed by April 2020.
3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 294 across 1,241 observational studies indexed under Heart Diseases.
Browse Heart Diseases studies →Hyeon-Cheol Gwon is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Ischemic heart disease with percutaneous coronary intervention with stenting
Exclusion Criteria:
No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
Device: BioMimeTM Stent, Ultimaster® Stent
No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
Device: BioMimeTM Stent, Ultimaster® Stent
The incidence of 1-year target lesion failure
The incidence of 1-year target lesion failure (combination of cardiac death, target vessel myocardial infarction, and target vessel revascularization).
Time frame: 1-year
Incidence of 30-day and 2-year target lesion failure
Time frame: 30-day and 2-year
Incidence of 30-day, 1-year, and 2-year deaths
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year cardiac events
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year myocardial infarction
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year target vessel myocardial infarction
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year revascularization
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year target revascularization
Time frame: 30-day, 1-year, and 2-year
Incidence of 30-day, 1-year, and 2-year stroke
Time frame: 30-day, 1-year, and 2-year
Incidence of acute stent thrombosis at 24 hours, subacute stent thrombosis at 30 days, and stent thrombosis at 1 and 2 years
Time frame: 24 hours, 30 days, 1 and 2 years
Plan to share: No
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.